


CLAIMS

We claim:

1. A compound of the formula:



or a pharmaceutically acceptable derivative or prodrug thereof; wherein

Y is selected from O, NH, N(R), S, S(O) or S(O)₂;

X is selected from O, NH or N(R);

R¹ and R² are each independently selected from H,

a C₁-C₆ straight chain or branched alkyl or alkenyl group, optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NH₂, S(O)₂NHR or R; a 5-7

membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NH₂, S(O)₂NHR

or R; or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NH₂, S(O)₂NHR or R; wherein said heterocyclic ring contains 1 to 4 heteroatoms, each of which

heteroatoms are independently selected from N, O, S, SO or SO₂; and

R is selected from a C₁-C₆ straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.

2. The compound according to claim 1, wherein the compound is selected from any one of the compounds depicted in Table 1.

3. A pharmaceutical composition comprising an amount of a compound according to either of claims 1 or 2 effective to inhibit JNK, and a pharmaceutically acceptable carrier.

4. A method of treating or preventing inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with proinflammatory cytokines in a patient, said method comprising administering to said patient a composition according to claim 3.

5. The method according to claim 4, wherein said method is used to treat or prevent an inflammatory disease selected from acute pancreatitis, chronic

pancreatitis, asthma, allergies, or adult respiratory distress syndrome.

6. The method according to claim 4, wherein
5 said method is used to treat or prevent an autoimmune
disease selected from glomerulonephritis, rheumatoid
arthritis, systemic lupus erythematosus, scleroderma,
chronic thyroiditis, Graves' disease, autoimmune
gastritis, diabetes, autoimmune hemolytic anemia,
10 autoimmune neutropenia, thrombocytopenia, atopic
dermatitis, chronic active hepatitis, myasthenia gravis,
multiple sclerosis, inflammatory bowel disease, ulcerative
colitis, Crohn's disease, psoriasis, or graft vs. host
disease.

7. The method according to claim 4, wherein
said method is used to treat or prevent a destructive bone
disorders selected from osteoarthritis, osteoporosis or
multiple myeloma-related bone disorder.

8. The method according to claim 4, wherein
said method is used to treat or prevent a proliferative
disease selected from acute myelogenous leukemia, chronic
myelogenous leukemia, metastatic melanoma, Kaposi's
25 sarcoma, or multiple myeloma.

9. The method according to claim 4, wherein
said method is used to treat or prevent neurodegenerative
disease selected from Alzheimer's disease, Parkinson's
30 disease, amyotrophic lateral sclerosis, Huntington's
disease, cerebral ischemia or neurodegenerative disease

caused by traumatic injury, glutamate neurotoxicity or hypoxia.

10. The method according to claim 4, wherein
said method is used to treat or prevent
5 ischemia/reperfusion in stroke or myocardial ischemia,
renal ischemia, heart attacks, organ hypoxia or thrombin-
induced platelet aggregation.

11. The method according to claim 4, wherein
10 said method is used to treat or prevent a condition
associated with T-cell activation or pathologic immune
responses.

12. The method according to claim 4, wherein
15 said method is used to treat or prevent an angiogenic
disorder selected from solid tumors, ocular
neovascularization, or infantile haemangiomas.